Jasper Therapeutics, Inc. Nonoperating Income (Expense)
Financial Statements › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2026-08-14
- Jasper Therapeutics, Inc. nonoperating income (expense) for the quarter ending 2026-06-30 was $6.45M, a 1726.35% increase year-over-year.
- Jasper Therapeutics, Inc. nonoperating income (expense) for the quarter ending 2026-03-31 was $9.78M, a 1642.96% increase year-over-year.
- Jasper Therapeutics, Inc. nonoperating income (expense) for the quarter ending 2025-12-31 was $6.74M, a 598.96% increase year-over-year.
- Jasper Therapeutics, Inc. nonoperating income (expense) for the quarter ending 2025-09-30 was $430.00K, a 65.65% decline year-over-year.
- Jasper Therapeutics, Inc. nonoperating income (expense) for fiscal 2025 was $8.08M, a 62.62% increase from fiscal 2024.
- Jasper Therapeutics, Inc. nonoperating income (expense) for fiscal 2024 was $4.97M, a 13.06% increase from fiscal 2023.
- Jasper Therapeutics, Inc. nonoperating income (expense) for fiscal 2023 was $4.40M.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.45M 10-Q · filed 2026-08-14 | $16.23M 10-Q · filed 2026-08-14 | $22.96M derived: sum of 3 quarters · filed 2026-08-14 | $23.39M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $9.78M 10-Q · filed 2026-05-14 | $16.52M derived: sum of 2 quarters · filed 2026-05-14 | $16.95M derived: sum of 3 quarters · filed 2026-05-14 | $17.30M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $6.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $7.17M derived: sum of 2 quarters · filed 2026-03-30 | $7.52M derived: sum of 3 quarters · filed 2026-08-14 | $8.08M 10-K · filed 2026-03-30 |
| 2025-09-30 | $430.00K 10-Q · filed 2025-11-10 | $783.00K derived: sum of 2 quarters · filed 2026-08-14 | $1.34M 10-Q · filed 2025-11-10 | $2.31M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $353.00K 10-Q · filed 2026-08-14 | $914.00K 10-Q · filed 2026-08-14 | $1.88M derived: sum of 3 quarters · filed 2026-08-14 | $3.13M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $561.00K 10-Q · filed 2026-05-14 | $1.52M derived: sum of 2 quarters · filed 2026-05-14 | $2.78M derived: sum of 3 quarters · filed 2026-05-14 | $4.19M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $964.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.22M derived: sum of 2 quarters · filed 2026-03-30 | $3.63M derived: sum of 3 quarters · filed 2026-03-30 | $4.97M 10-K · filed 2026-03-30 |
| 2024-09-30 | $1.25M 10-Q · filed 2025-11-10 | $2.66M derived: sum of 2 quarters · filed 2025-11-10 | $4.01M 10-Q · filed 2025-11-10 | $5.15M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $1.41M 10-Q · filed 2025-08-13 | $2.75M 10-Q · filed 2025-08-13 | $3.90M derived: sum of 3 quarters · filed 2025-08-13 | $5.72M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.34M 10-Q · filed 2025-05-12 | $2.49M derived: sum of 2 quarters · filed 2025-05-12 | $4.31M derived: sum of 3 quarters · filed 2025-05-12 | $6.05M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $2.96M derived: sum of 2 quarters · filed 2025-02-28 | $4.71M derived: sum of 3 quarters · filed 2025-02-28 | $4.40M 10-K · filed 2025-02-28 |
| 2023-09-30 | $1.82M 10-Q · filed 2024-11-07 | $3.56M derived: sum of 2 quarters · filed 2024-11-07 | $3.25M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $1.75M 10-Q · filed 2024-08-13 | $1.43M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$313.00K 10-Q · filed 2024-05-14 |